FI932695A0 - Angiotensin I kymas-inhibitorer inklusive humant hjaertkymas - Google Patents

Angiotensin I kymas-inhibitorer inklusive humant hjaertkymas

Info

Publication number
FI932695A0
FI932695A0 FI932695A FI932695A FI932695A0 FI 932695 A0 FI932695 A0 FI 932695A0 FI 932695 A FI932695 A FI 932695A FI 932695 A FI932695 A FI 932695A FI 932695 A0 FI932695 A0 FI 932695A0
Authority
FI
Finland
Prior art keywords
chyme
angiotensin
inclusive
humans
inhibitor
Prior art date
Application number
FI932695A
Other languages
English (en)
Other versions
FI932695A (fi
Inventor
Dennis J Hoover
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of FI932695A0 publication Critical patent/FI932695A0/fi
Publication of FI932695A publication Critical patent/FI932695A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI932695A 1992-06-12 1993-06-11 Angiotensin i kymas-inhibitorer inklusive humant hjaertkymas FI932695A (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89772392A 1992-06-12 1992-06-12

Publications (2)

Publication Number Publication Date
FI932695A0 true FI932695A0 (fi) 1993-06-11
FI932695A FI932695A (fi) 1993-12-13

Family

ID=25408314

Family Applications (1)

Application Number Title Priority Date Filing Date
FI932695A FI932695A (fi) 1992-06-12 1993-06-11 Angiotensin i kymas-inhibitorer inklusive humant hjaertkymas

Country Status (5)

Country Link
EP (1) EP0644892A1 (fi)
JP (1) JP2668003B2 (fi)
CA (1) CA2137832C (fi)
FI (1) FI932695A (fi)
WO (1) WO1993025574A1 (fi)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9524267D0 (en) * 1995-11-28 1996-01-31 Isis Innovation Enzyme inhibitor and method
NZ334543A (en) * 1996-09-10 2000-06-23 Thomae Gmbh Dr K Modified amino acids for production of antibodies and labelled compounds suitable for RIA and ELISA assays
IL129407A0 (en) * 1996-10-18 2000-02-17 Vertex Pharma Inhibitors of serine proteases particularly hepatitis C virus NS3 protease pharmaceutical compositions containing the same and the use thereof
SI0932617T1 (en) * 1996-10-18 2002-06-30 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
KR20000052775A (ko) * 1996-10-25 2000-08-25 가마쿠라 아키오 신규한 헤테로사이클릭 아미드 화합물 및 의약으로서의 그의 용도
US20030069231A1 (en) * 1999-10-12 2003-04-10 Klaus Rudolf Modified aminoacids, pharmaceuticals containing these compounds and method for their production
US6300337B1 (en) 1998-02-17 2001-10-09 Nippon Kayaku Kabushiki Kaisha Acetamide derivative and use thereof
KR20010074838A (ko) * 1998-08-20 2001-08-09 요시다 쇼지 안 순환 장해의 예방 또는 치료제
US6432978B1 (en) * 1998-12-01 2002-08-13 Meiji Seika Kaisha, Ltd. SF2809-I,II,III,IV,V and VI substances exhibiting chymase-inhibiting activities
WO2001032214A1 (fr) 1999-11-01 2001-05-10 Suntory Limited Inhibiteurs diriges contre le depot de lipides dans les vaisseaux, contenant des substances inhibant la chymase
US6500835B2 (en) 2000-02-22 2002-12-31 Suntory Limited Preventive or therapeutic drugs for fibrosis containing chymase inhibitors as the active ingredient
HUP0201287A3 (en) 2000-02-22 2003-02-28 Daiichi Asubio Pharma Co Ltd Preventive or therapeutic drugs for various eosinphilia-related diseases containing quinazoline derivative chymase inhibitors as the active ingredient
HUP0201282A3 (en) 2000-02-22 2003-02-28 Daiichi Asubio Pharma Co Ltd Preventive or therapeutic drugs for dermatitises containing quinazolindione derivative chymase inhibitors as the active ingredient
CA2411165A1 (en) * 2000-05-02 2002-12-11 Meiji Seika Kaisha, Ltd. Novel indole derivatives exhibiting chymase-inhibitory activities and process for preparation thereof
AU2002222933A1 (en) * 2000-07-13 2002-01-30 Millennium Pharamaceuticals, Inc. Inhibitors of factor xa
GB0021315D0 (en) * 2000-08-30 2000-10-18 Dainippon Pharmaceutical Co Heterocyclic compounds and intermediates thereof
WO2002059077A1 (fr) 2001-01-26 2002-08-01 Takeda Chemical Industries, Ltd. Derivés aminoéthanol
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
KR101187693B1 (ko) 2003-05-09 2012-10-05 도레이 카부시키가이샤 신장질환의 치료 또는 예방제
MY148123A (en) 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7906619B2 (en) 2006-07-13 2011-03-15 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
WO2010068760A2 (en) 2008-12-10 2010-06-17 Achillion Pharmaceuticals, Inc. New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US9085607B2 (en) 2013-03-15 2015-07-21 Achillion Pharmaceuticals, Inc. ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof
MX2015013020A (es) 2013-03-15 2016-06-10 Achillion Pharmaceuticals Inc Polimorfos de sovaprevir y metodos de fabricacion de los mismos.
DK3472149T3 (da) 2016-06-21 2023-11-27 Orion Ophthalmology LLC Heterocykliske prolinamidderivater
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499082A (en) * 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
ZA905737B (en) * 1989-07-26 1991-05-29 Merrell Dow Pharma Novel peptidase inhibitors
ATE181925T1 (de) * 1991-05-23 1999-07-15 Merrell Pharma Inc Hemmstoffe für kathepsin-g und elastase zur verhütung von bindegewebsabbau

Also Published As

Publication number Publication date
WO1993025574A1 (en) 1993-12-23
CA2137832C (en) 2000-09-26
FI932695A (fi) 1993-12-13
EP0644892A1 (en) 1995-03-29
JP2668003B2 (ja) 1997-10-27
JPH07507069A (ja) 1995-08-03
CA2137832A1 (en) 1993-12-23

Similar Documents

Publication Publication Date Title
FI932695A0 (fi) Angiotensin I kymas-inhibitorer inklusive humant hjaertkymas
NO932005D0 (no) Angiotensin-ii-antagonister
DE69222931T2 (de) Bagger- und Anwendungsverfahren
NO942064D0 (no) yminhibitorer
DE69419995T2 (de) Dämpfungsglied
DE69333825D1 (de) BiCDMOS Strukturen
NO943025D0 (no) Tredjepartsbelastning
BR9506832A (pt) N-pirazolilanilinas e n-pirazolilaminopiridinas
DE69214428D1 (de) Bagger- und Anwendungsverfahren
DK0750080T3 (da) Konstruktioner
FI943513A0 (fi) Kolekystokiniiniantagonisteina käyttökelpoisia 3-fenyyliureidoatsepin-2-oneja ja -bentsatsepin-2-oneja
ITMI921571A1 (it) Azaciclo e azabiciclo alchiliden idrossilamine
FI1031U1 (fi) En troakar
DE59308210D1 (de) Personendurchgang
DK83692D0 (da) Forbindelser
KR930008914U (ko) 수로겸용 비탈면 보호블록
ATA83492A (de) Zerstörladung
KR950008227U (ko) 바둑판
KR940026285U (ko) 바둑판
KR950005742U (ko) 바둑판
KR950010970U (ko) 조립식 바둑판 겸용 장기판
ITMI931648A1 (it) Azaciclo e azabiciclo ammidi
DE59404785D1 (de) Abwehr-einrichtung
SE9203239D0 (sv) I l-list
KR960003702U (ko) 펜던트 및 그를 활용한 넥타이 세트